StreetInsider.com News Articles

Form 4 Artiva Biotherapeutics, For: Jun 12 Filed by: RA Capital Nexus Fund, L.P.

Tue, 16 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26655531.html

Form 4 Artiva Biotherapeutics, For: Jun 12 Filed by: RA Capital Nexus Fund, L.P.

Tue, 16 Jun 2026 18:08:00 -0400

si-local-file:///var/storage/secattach/20260616/26655531.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 15 Jun 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26649048.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

Mon, 15 Jun 2026 19:37:00 -0400

si-local-file:///var/storage/secattach/20260615/26649048.html

Form 4 Artiva Biotherapeutics, For: Jun 09 Filed by: RA Capital Nexus Fund, L.P.

Thu, 11 Jun 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260611/26637177.html

Form 4 Artiva Biotherapeutics, For: Jun 09 Filed by: RA Capital Nexus Fund, L.P.

Thu, 11 Jun 2026 19:36:00 -0400

si-local-file:///var/storage/secattach/20260611/26637177.html

Artiva receives FDA RMAT designation for rheumatoid arthritis therapy

Mon, 08 Jun 2026 06:30:50 -0400

Artiva Biotherapeutics Inc. (NASDAQ: ARTV) announced that the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to its AlloNK therapy combined with rituximab for treating refractory rheumatoid arthritis.

The San Diego-based biotechnology company presented clinical data for AlloNK at the European Alliance of Associations for Rheumatology 2026 Congress in London. The therapy is an allogeneic, off-the-shelf natural killer cell treatment designed to enhance antibody-dependent cellular cytotoxicity when combined with monoclonal antibodies.

In the company-sponsored Phase 2a basket trial, 71% of rheumatoid arthritis patients with six months of follow-up achieved an ACR50 response, according to data with an April 3,

Artiva receives FDA RMAT designation for rheumatoid arthritis therapy

Mon, 08 Jun 2026 06:30:50 -0400

In the company-sponsored Phase 2a basket trial, 71% of rheumatoid arthritis patients with six months of follow-up achieved an ACR50 response, according to data with an April 3,

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Mon, 08 Jun 2026 06:30:00 -0400

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis
Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases
Rheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trial
Safety and translational data support AlloNK’s potential as an outpatient-administered, community-compatible deep B-cell depleting therapy
U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Mon, 08 Jun 2026 06:30:00 -0400

Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis
Late-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseases
Rheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trial
Safety and translational data support AlloNK’s potential as an outpatient-administered, community-compatible deep B-cell depleting therapy
U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: GC Corp.

Thu, 28 May 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260528/26568175.html

Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: GC Corp.

Thu, 28 May 2026 16:39:00 -0400
si-local-file:///var/storage/secattach/20260528/26568175.html

Form 4 Artiva Biotherapeutics, For: May 11 Filed by: GC Corp.

Thu, 28 May 2026 16:34:00 -0400
si-local-file:///var/storage/secattach/20260528/26568072.html

Form 4 Artiva Biotherapeutics, For: May 11 Filed by: GC Corp.

Thu, 28 May 2026 16:34:00 -0400
si-local-file:///var/storage/secattach/20260528/26568072.html

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Thu, 28 May 2026 08:00:00 -0400

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT.

To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available

Artiva Biotherapeutics (ARTV) Reiterated at Overweight by Cantor Fitzgerald

Tue, 26 May 2026 07:22:33 -0400

Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and $40.00 price target on Artiva Biotherapeutics (NASDAQ: ARTV).
The analyst commented, "Following that update, we hosted Artiva's CEO, Fred Aslan, for a webinar to review the company's differentiated AlloNK safety profile, strategy in refractory rheumatoid arthritis (RA), positive Phase 2 efficacy data, path to market and manufacturing capabilities. This company is still way off investor radar screens. With its compelling RA data, strong early rheumatologist feedback and a clearly differentiated profile vs the broader B-cell depleting field, ARTV has moved into our top-pick list for smidcaps. We see a clear path

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Raymon Heather

Tue, 19 May 2026 21:53:00 -0400
si-local-file:///var/storage/secattach/20260519/26523452.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Raymon Heather

Tue, 19 May 2026 21:53:00 -0400
si-local-file:///var/storage/secattach/20260519/26523452.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Horan Christopher

Tue, 19 May 2026 21:52:00 -0400
si-local-file:///var/storage/secattach/20260519/26523451.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Horan Christopher

Tue, 19 May 2026 21:52:00 -0400
si-local-file:///var/storage/secattach/20260519/26523451.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Banerjee Subhashis

Tue, 19 May 2026 21:51:00 -0400
si-local-file:///var/storage/secattach/20260519/26523449.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Banerjee Subhashis

Tue, 19 May 2026 21:51:00 -0400
si-local-file:///var/storage/secattach/20260519/26523449.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Bush Jennifer

Tue, 19 May 2026 21:51:00 -0400
si-local-file:///var/storage/secattach/20260519/26523450.html

Form 4 Artiva Biotherapeutics, For: May 19 Filed by: Bush Jennifer

Tue, 19 May 2026 21:51:00 -0400
si-local-file:///var/storage/secattach/20260519/26523450.html